September 2006
Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p1
Trade Publication
The article reports on an agreement signed by Spherix Inc. with Anaclim LLC to conduct the U.S. portion of its Phase 3 clinical trial on the use of Naturlose as a treatment for Type 2 diabetes. The companies have decided to split the trial into portions to cover all required demographic groups. Gleneagles CRC was selected to conduct the main part of the trial in Australia. The significance of the deal for Anaclim is cited.


Related Articles

  • Spherix Soars on D-tagatose Results, Starts Partner Hunt. Boggs, Jennifer // BioWorld Today;10/8/2010, Vol. 21 Issue 195, p1 

    The article reports on the claim of Spherix Inc. that its D-tagatose, a product that was originally developed as reduced-calorie sugar substitute, reached statistical significance in a Phase III trial in Type II diabetes. The news resulted to 33% increase in the company's share price in early...

  • The OR IGIN Trial: Basal Insulin vs Standard Care for Early Type 2 Diabetes. Kuritzky, Louis // Internal Medicine Alert;9/15/2012, Vol. 34 Issue 17, p135 

    The article informs about a comparative clinical trial between basal insulin and standard treatment for early type 2 diabetes to improve cardiovascular outcomes.

  • Optimal testing of multiple hypotheses with common effect direction. Richard M. Bittman; Joseph P. Romano; Carlos Vallarino; Michael Wolf // Biometrika;Jun2009, Vol. 96 Issue 2, p399 

    We present a theoretical basis for testing related endpoints. Typically, it is known how to construct tests of the individual hypotheses, but not how to combine them into a multiple test procedure that controls the familywise error rate. Using the closure method, we emphasize the role of...

  • ConjuChem's Conjugated GLP-1 Agonist Hits Phase II Endpoints. Boggs, Jennifer // BioWorld Today;12/5/2008, Vol. 19 Issue 236, p1 

    The article reports that preliminary results from two phase II trials of ConjuChem Biotechnologies Inc.showed that PC DAC:Exendin-4 significantly reduced HbA1c and weight in type II diabetes patients compared to placebo. The biotechnology company is hoping those data will catch the attention of...

  • Clinical Trials Update. Slomski, Anita // JAMA: Journal of the American Medical Association;11/27/2013, Vol. 310 Issue 20, p2139 

    The section offers updates on several clinical trials. In the 40-month cohort study Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes, it has been observed that individuals with type 2 diabetes and depression had accelerated cognitive decline. Based on a study of...

  • Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy. Ki Young Na; Dong Ki Kim; Sung Gyun Kim; Young-Ki Lee; Chun Soo Lim // Trials;2013, Vol. 14 Issue 1, p1 

    Background: Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Cardiovascular (CV) complications are the most common cause of death among ESRD patients. Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects. Methods: This is a...

  • RECRUITMENT OF BLACK WOMEN WITH TYPE 2 DIABETES INTO A SELF-MANAGEMENT INTERVENTION TRIAL. Newlin, Kelley; Melkus, Gail D'Eramo; Jefferson, Vanessa; Langerman, Susan; Womack, Julie; Chyun, Deborah // Ethnicity & Disease;Autumn2006, Vol. 16 Issue 4, p956 

    The article assesses the relationship of recruitment methods with the enrollment status of African American women with type 2 diabetes screened for entry into a randomized clinical trial. The results of the study confirmed previous findings indicating that African American women may be...

  • A review of methods used in assessing nonserious adverse drug events in observational studies among type 2 diabetes mellitus patients.  // Health & Quality of Life Outcomes;2011, Vol. 9 Issue 1, p83 

    The article reviews a method used in assessing nonserious adverse drug events (ADEs) in observational studies among patients with type 2 diabetes mellitus. It mentions the observational studies rely on methods that are not suitable for identifying all possible ADEs. Further it suggests that...

  • Targacept Announces Top-Line Results from 2 Exploratory Phase 2 Studies of TC- 6987.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article presents top-line results from two phase II clinical trials done by Targacept Inc. for its product candidate TC-6987, one in asthma and one in type 2 diabetes. It informs that in asthma study, the product met protocol-defined success criteria while in type 2 diabetes study, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics